Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race between Clearance, Tolerance, Neutralization, and Escape

Annual Review of Virology

Volumn 4, Issue , 2017, Pages 511-534

  Mingozzi, Federico ^a,b   High, Katherine A ^c  

^a Genethon and INSERM U951 ^*  (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Ophthalmology   (United States)

Author keywords

AAV; Gene therapy; Immunomonitoring; Immunotoxicity; Neutralizing antibodies; Tolerance

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; NEUTRALIZING ANTIBODY;

ADENO ASSOCIATED VIRUS; ARTICLE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; EYE; GENE TRANSFER; HOST; HUMAN; IMMUNE RESPONSE; INTRAVITREAL DRUG ADMINISTRATION; LIVER; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RETINA; TRANSGENE; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS MORPHOLOGY; WILD TYPE; ACTIVE IMMUNIZATION; ANIMAL; BIOSYNTHESIS; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE;

ANIMALS; ANTIBODIES, NEUTRALIZING; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, ACTIVE; MICE;

EID: 85030325583     PISSN: 2327056X     EISSN: 23270578     Source Type: Journal    
DOI: 10.1146/annurev-virology-101416-041936     Document Type: Article

References (142)

1. Blacklow NR, Hoggan MD, Rowe WP. 1967. Isolation of adenovirus-associated viruses from man. PNAS 58:1410-15
2. Sonntag F, Schmidt K, Kleinschmidt JA. 2010. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. PNAS 107:10220-25
3. Yan Z, Zak R, Zhang Y, Engelhardt JF. 2004. Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J. Virol. 79:364-79
4. Xiao X, Li J, Samulski RJ. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72:2224-32
5. Urabe M, Ding C, Kotin RM. 2002. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13:1935-43
6. van der Loo JCM, Wright JF. 2016. Progress and challenges in viral vector manufacturing. Hum. Mol. Genet. 25:R42-52
7. Grieger JC, Soltys SM, Samulski RJ. 2016. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol. Ther. 24:287-97
8. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-45
9. Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, et al. 2016. An essential receptor for adenoassociated virus infection. Nature 530:108-12
10. Ding W, Zhang L, Yan Z, Engelhardt JF. 2005. Intracellular trafficking of adeno-associated viral vectors. Gene Ther. 12:873-80
11. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, et al. 2007. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13:419-22
12. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, et al. 2012. Humoral and cellular capsidspecific immune responses to adeno-associated virus type 1 in randomized healthy donors. J. Immunol. 188:6418-24
13. Hui DJ, Edmonson SC, Podsakoff GM, Pien GC, Ivanciu L, et al. 2015. AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. Mol. Ther. Methods Clin. Dev. 2:15029
14. FlaniganKM,Campbell K, ViolletL,WangW,Gomez AM, et al. 2013. Anti-dystrophinTcell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum. Gene Ther. 24:797-806
15. Medawar PB. 1948. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29:58-69
16. Willett K, Bennett J. 2013. Immunology of AAV-mediated gene transfer in the eye. Front. Immunol. 4:261
17. Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, et al. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358:2231-39
18. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, et al. 2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358:2240-48
19. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, et al. 2008. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19:979-90
20. Bainbridge JWB, Mehat MS, Sundaram V, Robbie SJ, Barker SE, et al. 2015. Long-term effect of gene therapy on Leber's congenital amaurosis. N. Engl. J. Med. 372:1887-97
21. Russell S, Bennett J, Wellman JA, ChungDC, Yu ZF, et al. 2017. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in subjects with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. https://doi.org/10.1016/S0140-6736(17)31868-8
22. Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, et al. 2016. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 388:661-72
23. Amado D, Mingozzi F, Hui D, Bennicelli JL, Wei Z, et al. 2010. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci. Translational Med. 2:21ra16
24. MacLachlan TK, Lukason M, Collins M, Munger R, Isenberger E, et al. 2011. Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Mol. Ther. 19:326-34
25. Uretsky S, Sahel JA, Galy A, Thomasson N, Honnet G, et al. 2015. A recombinant AAV2/2 carrying the wild-type ND4 gene for the treatment of LHON: preliminary results of a first-in-man study and upcoming pivotal efficacy trials. Presented at 12th Int. Symp. Ocul. Pharmacol. Ther. (ISOPT Clin.), July 9-12, Berlin
26. Mingozzi F, High KA. 2011. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12:341-55
27. Thomson AW, Knolle PA. 2010. Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 10:753-66
28. Lerut J, Sanchez-Fueyo A. 2006. An appraisal of tolerance in liver transplantation. Am. J. Transplant. 6:1774-80
29. Topal E, Ç atal F, Selimoglu MA, Karabiber H, Klc T, et al. 2014. Acquired atopic disease after liver transplantation in children; similarities to and differences from adults. Eur. J. Gastroenterol. Hepatol. 26:1055-59
30. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, et al. 2007. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110:2334-41
31. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, et al. 2003. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Investig. 111:1347-56
32. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, et al. 2007. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110:1132-40
33. Lüth S, Huber S, Schramm C, Buch T, Zander S, et al. 2008. Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J. Clin. Investig. 118:3403-10
34. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. 2004. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103:3700-9
35. Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, et al. 2013. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol. Med. 5:1698-709
36. Le Guen V, Judor JP, Boeffard F, Gauttier V, Ferry N, et al. 2017. Alloantigen gene transfer to hepatocytes promotes tolerance to pancreatic islet graft by inducing CD8+ regulatory T cells. J. Hepatol. 66:765-77
37. Breous E, Somanathan S, Wilson JM. 2010. BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. Mol. Ther. 18:766-74
38. D'Avola D, Lopez-Franco E, Sangro B, Paneda A, Grossios N, et al. 2016. Phase I open label liverdirected gene therapy clinical trial for acute intermittent porphyria. J. Hepatol. 65:776-83
39. Manno CS, Arruda VR, Pierce GF, Glader B, Ragni M, et al. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12:342-47
40. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, et al. 2011. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365:2357-65
41. Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, et al. 2014. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371:1994-2004
42. Zhu J, Huang X, Yang Y. 2009. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J. Clin. Investig. 119:2388-98
43. Sudres M, Ciré S, Vasseur V, Brault L, Da Rocha S, et al. 2012. MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol. Ther. 20:1571-81
44. Rogers GL, MartinoAT, AslanidiGV, JayandharanGR, Srivastava A, HerzogRW.2011 Innate immune responses to AAV vectors. Front. Microbiol. 2:194
45. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, et al. 2011. The genome of selfcomplementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117:6459-68
46. Hösel M, Broxtermann M, Janicki H, Esser K, Arzberger S, et al. 2011. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 55:287-97
47. Douar AM, Poulard K, Stockholm D, Danos O. 2001. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75:1824-33
48. Yan Z, Zak R, Luxton GWG, RitchieTC, Bantel-Schaal U, Engelhardt JF. 2002. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol. 76:2043-53
49. Finn JD, Hui D, Downey HD, Dunn D, Pien GC, et al. 2010. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation onMHCclass I following transduction. Mol. Ther. 18:135-42
50. Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, et al. 2006. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat. Med. 12:967-71
51. Chadeuf G, Ciron C, Moullier P, Salvetti A. 2005. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther. 12:744-53
52. Hauck B,Murphy SL, Smith PH, Qu G, Liu X, et al. 2009. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol. Ther. 17:144-52
53. George LA, Sullivan SK, Giermasz A, Ducore JM, Teitel JM, et al. 2016. SPK-9001: adeno-associated virus mediated gene transfer for hemophilia B achieves sustained mean factor IX activity levels of >30% without immunosuppression. Blood 128:3
54. Li C, Goudy K, Hirsch M, Asokan A, Fan Y, et al. 2009. Cellular immune response to cryptic epitopes during therapeutic gene transfer. PNAS 106:10770-74
55. Li C, Hirsch M, DiPrimio N, Asokan A, Goudy K, et al. 2009. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J. Virol. 83:6817-24
56. Wang L, Figueredo J, Calcedo R, Lin J,Wilson JM. 2007. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum. Gene Ther. 18:185-94
57. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, et al. 2010. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28:79-82
58. Li C, Hirsch M, Asokan A, Zeithaml B,Ma H, et al. 2007. Adeno-associated virus type 2 (AAV2) capsidspecific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J. Virol. 81:7540-47
59. Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, et al. 2013. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121:2224-33
60. Wu TL, Li H, Faust SM, Chi E, Zhou S, et al. 2014. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. Mol. Ther. 22:42-51
61. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. 2006. Loss of Siglec expression on T lymphocytes during human evolution. PNAS 103:7765-70
62. Li H, Lasaro MO, Jia B, Lin SW, Haut LH, et al. 2011. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol. Ther. 19:2021-30
63. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, et al. 2009. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Investig. 119:1688-95
64. Scholten KBJ, Schreurs MWJ, Ruizendaal JJ, Kueter EWM, Kramer D, et al. 2005. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin. Immunol. 114:119-29
65. Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, et al. 2013. CpG-depleted adeno-associated virus vectors evade immune detection. J. Clin. Investig. 123:2994-3001
66. Mingozzi F, Anguela XM, Pavani G, Chen Y, Davidson RJ, et al. 2013. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5:194ra92
67. Schwartz M, Deczkowska A. 2016. Neurological disease as a failure of brain-immune crosstalk: the multiple faces of neuroinflammation. Trends Immunol. 37:668-79
68. KamranN, Calinescu A, CandolfiM, ChandranM,Mineharu Y, et al. 2016. Recent advances and future of immunotherapy for glioblastoma. Expert Opin. Biol. Ther. 16:1245-64
69. SagarD, Foss C, El Baz R, Pomper MG, Khan ZK, Jain P. 2011. Mechanisms of dendritic cell trafficking across the blood-brain barrier. J. Neuroimmune Pharmacol. 7:74-94
70. Rudolph H, Klopstein A, Gruber I, Blatti C, Lyck R, Engelhardt B. 2016. Postarrest stalling rather than crawling favors CD8+ over CD4+ T-cell migration across the blood-brain barrier under flow in vitro. Eur. J. Immunol. 46:2187-203
71. Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, et al. 2016. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 388:476-87
72. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, et al. 2013. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341:1233158
73. HocquemillerM, Giersch L, Audrain M, Parker S, Cartier N. 2016. Adeno-associated virus-based gene therapy for CNS diseases. Hum. Gene Ther. 27:478-96
74. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, et al. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097-105
75. Leone P, Shera D, McPhee SWJ, Francis JS, Kolodny EH, et al. 2012. Long-term follow-up after gene therapy for Canavan disease. Sci. Transl. Med. 4:165ra163
76. McPhee SWJ, Janson CG, Li C, Samulski RJ, Camp AS, et al. 2006. Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med. 8:577-88
77. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, et al. 2008. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19:463-74
78. Hwu WL,Muramatsu SI, Tseng SH, Tzen KY, LeeNC, et al. 2012. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med. 4:134ra61
79. Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, et al. 2011. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol. Ther. 19:251-59
80. Haurigot V, Marćo S, Ribera A, Garcia M, Ruzo A, et al. 2013. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J. Clin. Investig. 123:3254-71
81. Cearley CN, Wolfe JH. 2006. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther. 13:528-37
82. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. 2009. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27:59-65
83. Duque S, Joussemet B, Rivière C, Marais T, Dubreil L, et al. 2009. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17:1187-96
84. Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, et al. 2016. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34:204-9
85. Hudry E, Martin C, Gandhi S, György B, Scheffer DI, et al. 2016. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 23:380-92
86. Deleted in proof
87. Foster H, Sharp PS, Athanasopoulos T, Trollet C, Graham IR, et al. 2008. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther. 16:1825-32
88. Fraites TJ Jr., Schleissing MR, Shanely RA, Walter GA, Cloutier DA, et al. 2002. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol. Ther. 5:571-78
89. Lai Y, Yue Y, Liu M, Ghosh A, Engelhardt JF, et al. 2005. Efficient in vivo gene expression by transsplicing adeno-associated viral vectors. Nat. Biotechnol. 23:1435-39
90. Le Guiner C, Montus M, Servais L, Chérel Y, Francois V, et al. 2014. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol. Ther. 22:1923-35
91. LostalW,BartoliM,BourgN,Roudaut C, Bentaib A, et al. 2010. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum. Mol. Genet. 19:1897-907
92. Louboutin JP,Wang L,Wilson JM. 2005. Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. 7:442-51
93. Ross CJD, Twisk J, Bakker AC, Miao F, Verbart D, et al. 2006. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum. Gene Ther. 17:487-99
94. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, et al. 1998. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. PNAS 95:14384-88
95. Wang B, Li J, Xiao X. 2000. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. PNAS 97:13714-19
96. Gregorevic P, Allen JM, Minami E, BlankinshipMJ, HaraguchiM, et al. 2006. RAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12:787-89
97. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, et al. 1996. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. PNAS 93:14082-87
98. Xiao X, Li J, Samulski RJ. 1996. Efficient long-term gene transfer intomuscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70:8098-108
99. Herzog RW,Hagstrom JN, Kung SH,Tai SJ,Wilson JM, et al. 1997. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. PNAS 94:5804-9
100. Gaudet D, Stroes ES, Methot J, Brisson D, Tremblay K, et al. 2016. Long-term retrospective analysis of gene therapywith alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. Hum. Gene Ther. 27:916-25
101. Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, et al. 2013. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J. Clin. Investig. 123:5310-18
102. Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, et al. 2012. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 119:3038-41
103. Mack DL, Poulard K, Goddard MA, Latournerie V, Snyder JM, et al. 2017. Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol. Ther. 25:839-54
104. Guiner CL, Servais L, Montus M, Larcher T, Fraysse B, et al. 2016.
105. Adeno-associated virus vector (AAV)microdystrophin gene therapy prolongs survival and restores muscle function in the caninemodel of Duchenne muscular dystrophy (DMD). Mol. Ther. 24:S200
106. Matzinger P. 2002. The danger model: a renewed sense of self. Science 296:301-5
107. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, et al. 2010. Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363:1429-37
108. Haurigot V, Mingozzi F, Buchlis G, Hui DJ, Chen Y, et al. 2010. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol. Ther. 18:1318-29
109. Toromanoff A, Adjali O, Larcher T, Hill M, Guigand L, et al. 2010. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol. Ther. 18:151-60
110. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, et al. 2002. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum. Gene Ther. 13:1281-91
111. Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW. 2014. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J. Transl. Med. 12:25
112. Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, et al. 2010. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 99:26-33
113. Falk DJ, Soustek MS, Todd AG, Mah CS, Cloutier DA, et al. 2015. Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Mol. Ther.Methods Clin. Dev. 2:15007
114. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, et al. 2009. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsidspecific T cells. Blood 114:2077-86
115. Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, et al. 2015. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol. Ther. 23:192-201
116. Ferreira V, Twisk J, Kwikkers K, Aronica E, Brisson D, et al. 2014. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL S447X) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum. Gene Ther. 25:180-88
117. Ferreira V, Petry H, Salmon F. 2014. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front. Immunol. 5:82
118. BrantlyML, Chulay JD, Wang L, Mueller C,Humphries M, et al. 2009. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. PNAS 106:16363-68
119. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, et al. 2011. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing 1-antitrypsin: interim results. Hum. Gene Ther. 22:1239-47
120. Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, et al. 2017. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for 1-antitrypsin deficiency. PNAS 114:1655-59
121. Velazquez VM, Bowen DG, Walker CM. 2009. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. Blood 113:538-45
122. Calcedo R, Morizono H, Wang L, McCarter R, He J, et al. 2011. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol. 18:1586-88
123. Erles K, Sebokova P, Schlehofer JR. 1999. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59:406-11
124. Li C, NarkbunnamN, Samulski RJ, Asokan A,Hu G, et al. 2011. Neutralizing antibodies against adenoassociated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 19:288-94
125. Gao GP, Alvira MR,Wang L, Calcedo R, Johnston J,Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. PNAS 99:11854-59
126. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, et al. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21:704-12
127. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, et al. 2006. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108:3321-28
128. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, et al. 2006. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCIDmice. Blood 107:1810-17
129. Meliani A, Leborgne C, Triffault S, Jeanson-Leh L, Veron P, Mingozzi F. 2015. Determination of antiadeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum. Gene Ther. Methods 26:45-53
130. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, et al. 2002. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-72
131. Monahan PE. 2015. Gene therapy in an era of emerging treatment options for hemophilia B. J. Thromb. Haemost. 13(Suppl. 1):S151-60
132. Miesbach W, Tangelder M, Klamroth R, Schutgens R, Coppens M, et al. 2016. Updated results from a dose escalating study in adult patients with haemophilia B treated with AMT-060 (AAV5-hFIX) gene therapy. Haemophilia 22(Suppl. 4):151-52
133. Dimension Ther. 2017. Dimension announces interim topline results from ongoing phase 1/2 clinical program for DTX101, Dimension's lead AAV product candidate in development for adult patients with moderate/severe to severe hemophilia B. Press Release, Jan. 31. http://investors.dimensiontx.com/phoenix.zhtmlc= 254192&p=irol-newsArticle&ID=2240877
134. Pasi J, Wong W, Rangarajan S. 2016. Interim results of an open-label, phase 1/2 study of BMN 270, an AAV5-FVIII gene transfer in severe hemophilia A. Haemophilia 22(Suppl. 4):151-52
135. Chicoine LG, Montgomery CL, Bremer WG, Shontz KM, Griffin DA, et al. 2014. Plasmapheresis eliminates the negative impact of aav antibodies on microdystrophin gene expression following vascular delivery. Mol. Ther. 22:338-47
136. Monteilhet V, Saheb S, Boutin S, Leborgne C, Veron P, et al. 2011. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19:2084-91
137. Kishimoto TK, Ferrari JD, LaMothe RA, Kolte PN, Griset AP, et al. 2016. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat. Nanotechnol. 11:890-99
138. Mingozzi F, Chen Y, Murphy SL, Edmonson SC, Tai A, et al. 2012. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol. Ther. 20:1410-16
139. Unzu C, Hervás-Stubbs S, Sampedro A, Mauleon I, Mancheno U, et al. 2012. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J. Transl. Med. 10:122
140. Montenegro-Miranda PS, Bloemendaal LT, Kunne C, De Waart DR, Bosma PJ. 2011. Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors. Hum. Gene Ther. 22:605-12
141. Mingozzi F, Chen Y, Edmonson SC, Zhou S,Thurlings RM, et al. 2013. Prevalence and pharmacological modulation of humoral immunity toAAVvectors in gene transfer to synovial tissue. Gene Ther. 20:417-24
142. Mimuro J, Mizukami H, Hishikawa S, Ikemoto T, Ishiwata A, et al. 2013. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol. Ther. 21:318-23